Godavari Biorefineries Ltd

- There is no specific mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company has focused on debt reduction as part of its strategy to improve cash flow and reinvest strategically. - Samir Somaiya mentioned planned capital expenditure of INR 325 crores by FY29 for core activities, but no clear indication that this will be funded by new fundraising. - For the anti-cancer molecule project, the expected capital outlay over the next 2-3 years is stated to be not substantial enough to affect larger capex goals. - The company is monitoring customer commitments before undertaking large investments, such as in the biobutanol project, signaling cautious approach to new expenditures and funding. - Overall, no explicit details on fresh fundraising through debt or equity are disclosed at this time.

- Commissioning of a 200 KLPD fungible grain-based ethanol distillery planned in Q4 FY 2026 to enhance ethanol production capacity and feedstock flexibility. - Ongoing engineering work and customer commitment assessments for a new biobutanol project; investment dependent on securing strong customer commitments. - Planned preliminary efficacy trials for anti-cancer molecules, with a US-facing subsidiary being set up to facilitate out-licensing; capital outlay details to be shared in the next quarter but expected to be modest relative to larger capex goals. - Continued strategic investments to increase bio-based specialty chemicals and expand multi-feedstock ethanol capacity as part of growth and de-fossilization efforts. - Pilot project launched for converting industrial CO2 emissions to dimethyl ether (DME), supporting clean energy initiatives.

- Godavari Biorefineries expects overall revenue and EBITDA growth over the next 2-3 years, driven by multiple business segments. - Expansion of ethanol business through multi-feedstock capacity including the commissioning of a 200 KLPD grain-based ethanol plant in Q4 FY26. - Growth in bio-based specialty chemicals, aiming to increase their share within the chemical business, which has already contributed to improved profitability. - Scaling branded Jivana products (such as sugar, brown sugar, jaggery, turmeric) to strengthen price resilience and market presence. - Continued investments in debottlenecking chemical plants and exploring new product additions. - Sales from new ethanol plant depend on OMC tenders; expected annual capacity around 60 million liters. - Preliminary efficacy trials for anti-cancer drugs underway; potential future out-licensing may provide additional revenue streams. - Overall, growth will be influenced by policy, market demand, and successful execution across diversified segments.

- Godavari Biorefineries expects revenue and EBITDA growth over the next 2-3 years driven by: - Expansion in high-value bio-based specialty chemicals. - Increased multi-feedstock ethanol capacity including the upcoming grain-based ethanol facility (200 KLPD) commissioning in Q4 FY26. - Growth in branded consumer products under the Jivana brand. - Advances in drug discovery with potential out-licensing opportunities in 2-3 years. - Early signs of recovery in Q2 FY26 with 34% YoY revenue growth and EBITDA losses narrowing significantly. - Ethanol segment returned to positive EBITDA in Q2 FY26. - Continuous focus on cost optimization, debottlenecking, and strategic investments to improve margins. - Expectations of improved profitability driven by a better product mix and increasing share of specialty chemicals. - Overall, the company aims for sustainable value creation with steady improvement in operating earnings and profitability.

The transcript does not explicitly mention the current or expected order book or pending orders for Godavari Biorefineries Limited. However, relevant points related to future sales and tenders include: - Sales from the upcoming 200 KLPD grain-based ethanol plant in FY27 depend on tenders floated by Oil Marketing Companies (OMCs). - OMCs typically issue tenders annually, with the next expected around September 2026 for the latter half of FY27. - The plant capacity is about 60 million liters of ethanol per annum, with sales contingent on winning OMC tenders. - No specific order book or pending orders figures were disclosed. - The company is exploring out-licensing opportunities related to its anti-cancer drug development in the US market. In summary, order inflow is primarily dependent on government/OMC tenders and progress in partnership deals for pharma projects.